Figures cited from ClinicalTrials.gov study NCT05374993 (LastUpdatePostDate 2026-09-22 location add; status NOT_YET_RECRUITING as of that public row) and published bioaccess® country pages. Registry location rows are not a bioaccess® claim that we opened a new NCT action in this window. General information, not legal or regulatory advice. Confirm current MINSA, ethics, and FDA rules with qualified advisers. We name only the facility string and site-contact names those public NCT fields support. We do not invent an El Salvador hospital string (none appears on this NCT). We do not invent emails or metrics.
If you searched Universidad Interamericana de Panamá first-in-human, Universidad Interamericana Panama clinical trial, Interamericana Panama CRO, TriAgenics Zero3 Panama site, Universidad Interamericana de Panama NCT05374993, or “go direct Universidad Interamericana de Panamá,” you followed a campus string ClinicalTrials.gov now publishes on NCT05374993. Universidad Interamericana de Panamá in Panama City, Panama, is a real named university-campus string on that DEVICE_FEASIBILITY row (TriAgenics Inc; Zero3 System; planned enrollment 35). It is not a first-in-human medical-device CRO, and it is not the operator of the MINSA file.
bioaccess®’s position is simple and it is not adversarial: the university campus is the site. The First-in-Human CRO still owns MINSA, CNBI-registered ethics, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the campus or the named site contacts still have to rebuild that stack. An NCT location row is not a CRO.
This page is the named Panama City Universidad Interamericana de Panamá campus for the public Zero3 / TriAgenics location string. It is DISTINCT from Hospital Punta Pacífica Panama City, Hospital Paitilla Panama City, The Panama Clinic (CMS 95513), and CEVAXIN. Sharing Panama City is not a license to collapse them. Universidad Interamericana de Panamá is not Hospital Punta Pacífica. Universidad Interamericana de Panamá is not Hospital Paitilla. Universidad Interamericana de Panamá is not The Panama Clinic.
A separate public bioaccess® TriAgenics case study already describes a Zero3 first-in-human program framed across Panama and El Salvador. That page is a case study. It is not a Universidad Interamericana site-direct kill page, and it is not a license to invent an El Salvador hospital string on this intercept — ClinicalTrials.gov does not list an El Salvador facility on NCT05374993. This draft cites the Panama location row only.
Why the campus name wins the search — and why that is not a CRO
Device registries write the city, the facility, and a list of NCT IDs. They rarely write the CRO. On the public NCT05374993 row (LastUpdatePostDate 2026-09-22 location add), this campus sits here:
- Universidad Interamericana de Panamá (Panama City, Panama) — public NCT location string on NCT05374993 (DEVICE_FEASIBILITY; Zero3 System; TriAgenics Inc; planned enrollment 35; overall status NOT_YET_RECRUITING on that public row). Named site contacts on the same location block (public NCT fields): Aristides Joel Castillo Vásquez, DDS; Virgilio B. Castillero D, DDS. Study director on the registry: Leigh Colby, DDS (TriAgenics Inc).
Cite that single location row and those named NCT contact fields only. Do not invent ALL/DEVICE leftover-dump ranks for this campus — the 1 September 2026 LATAM facility sweep dump does not carry this string as a multi-study leftover campus. Do not clone Hospital Paitilla, Hospital Punta Pacífica, The Panama Clinic, or CEVAXIN onto this slug. Do not invent an El Salvador hospital.
That NCT ID is how a sponsor searching the university name, the Zero3 System, or the named DDS contacts lands on a campus without landing on an operator. We cite it as facility evidence. We will not invent additional principal investigators. We will not invent enrollment, clock, or cost metrics beyond what published bioaccess® Panama pages already state for the country stack.
That is the leak: a founder searching Universidad Interamericana de Panamá first-in-human, TriAgenics Panama, or Zero3 Panama site finds a DEVICE_FEASIBILITY location row without finding MINSA. A named university campus is still a site. An NCT location row is not a CRO.
What the public NCT actually says (facts only)
Public brief title: a first-in-human study of a novel 3rd molar tooth bud ablation procedure. Intervention type DEVICE; intervention name Zero3 System; lead sponsor TriAgenics Inc. Design on the public row: single-arm prospective, non-randomized; phases N/A; planned enrollment 35. Eligibility ages on the public row: 8 to 12 years. Primary outcome measure on the public row: incidence of wound healing and adverse events (90 days). Status on the cited pull: NOT_YET_RECRUITING. We will not invent timing, enrollment progress, or site activation claims beyond that public status.
The site is the site. The CRO is the operator.
A named university campus can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.
What the campus can typically do when a sponsor “goes direct”:
- Discuss investigator interest and whether a protocol can sit in an existing service line.
- Share institutional ethics-committee calendars and research rules.
- Quote visit, staffing, and local procedure costs for the cases they will physically run.
What the campus is not built to own for an investigational device:
- MINSA. MINSA is the national file for an investigational device in Panama. CNBI-registered ethics still has to sit. A hallway conversation on this campus is not that stack. Early-feasibility on the live Panama blogs is ethics-committee-driven — not an INVIMA/ANVISA-style second national device step. We will not invent a new Panamanian clock on this page. A hallway conversation at Universidad Interamericana de Panamá is not a Hospital Paitilla file and is not The Panama Clinic file.
- Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a site-contact email. See importer of record for clinical trial devices in Latin America.
- Clinical trial insurance. Required. We will not invent a campus-only premium here.
- ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
- The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
- Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-campus MSA will not stretch. The public TriAgenics case study already frames a two-country program story; this intercept still does not invent an El Salvador hospital string absent from NCT05374993.
Going direct to this campus — or emailing the DDS names ClinicalTrials.gov lists as location contacts — is how you confirm a room. It is not how you open an investigational file.
How MINSA actually works (the short version)
Use clinical-trials-panama. Panama’s Ministry of Health (MINSA), through the Dirección Nacional de Farmacia y Drogas, is the national file. Ethics review runs through institutional bioethics committees registered with the Comité Nacional de Bioética de la Investigación (CNBI). Published ethics typically 3–5 weeks; with bioaccess® coordination, protocol submission to first-patient enrollment averages 6–8 weeks on that hub. Per-patient costs there: $12,000–$22,000 in U.S. dollars. A hallway conversation at this university is not MINSA clearance.
Ask for a protocol-specific calendar. A campus email is not MINSA clearance. bioaccess® manages the file. That is CRO work, not site work.
All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.
Do not smear the campus
Universidad Interamericana de Panamá is a serious named Panamanian campus on the public registry for NCT05374993. A DEVICE_FEASIBILITY location row is registry evidence, not a punchline. Name the NCT site contacts as public fields. Do not invent additional investigators. Do not invent an El Salvador hospital. Use the site when the protocol fits. Hire the operator.
What the CRO still does after you have the campus on a slide
- Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
- Protocol, IB, ICF, insurance, and the MINSA / ethics packet.
- Importer of record and device accountability.
- Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
- ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.
The firm was founded in 2010. That is the operator layer around a campus string.
Colombia is still on the map
Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.
Frequently asked questions
Can I contract Universidad Interamericana de Panamá directly for a device FIH?
You can try. The campus can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by appearing on ClinicalTrials.gov, become your MINSA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.
Did bioaccess® run NCT05374993?
This intercept does not invent a new NCT-action claim for this window. A public bioaccess® TriAgenics / Zero3 case study already describes FIH work framed across Panama and El Salvador. That case study is not this facility kill page. We cite NCT05374993’s Panama location row as facility evidence for Universidad Interamericana de Panamá. We do not invent an El Salvador hospital string absent from that NCT.
Is this the same page as the TriAgenics case study?
No. bioaccessla.com/case-studies/triagenics is the public case study. This page is the Universidad Interamericana de Panamá site-direct search intercept for the NCT05374993 location string.
Is this the same page as Hospital Paitilla or The Panama Clinic?
No. Hospital Paitilla is a distinct Panama City campus. The Panama Clinic is CMS 95513 and must not be republished here. This page is Universidad Interamericana de Panamá only.
Who are Aristides Joel Castillo Vásquez, DDS and Virgilio B. Castillero D, DDS on this page?
They are the named site contacts ClinicalTrials.gov publishes on the Universidad Interamericana de Panamá location block for NCT05374993. We cite those public name fields. We do not invent titles beyond what the NCT prints. Emailing a named site contact is still not a CRO.
Should I invent an El Salvador hospital because the TriAgenics case study mentions El Salvador?
No. Do not invent an El Salvador hospital string. NCT05374993’s public locations list Universidad Interamericana de Panamá in Panama City, Panama. This intercept stays on that row.
Next step
If the search that brought you here was this campus, the Zero3 System, or the named NCT site contacts, start as the operator: contact bioaccess® or book from First-in-Human CRO. Related public case study (not this kill page): TriAgenics case study. Distinct Panama City siblings (do not merge): Hospital Punta Pacífica Panama City, Hospital Paitilla Panama City.
Julio G. Martinez-Clark, CEO · bioaccess®